GIA
ZOM

Gladstone Institutional Advisory’s Zomedica Corp. ZOM Stock Holding History

Gladstone Institutional Advisory’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55,058
Closed -$17K – 771
2021
Q4 		$17K Buy
55,058
+1,526
+3% +$687 ﹤0.01% 592
2021
Q3 		$28K Buy
53,532
+1,268
+2% +$748 ﹤0.01% 538
2021
Q2 		$44K Buy
+52,264
New +$48.7K 0.01% 511

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Gladstone Institutional Advisory's ZOM Position: Q1 2022 in Review

Gladstone Institutional Advisory sold out of Zomedica Corp. (ZOM) in Q1 2022, closing a stake of 55,058 shares — an estimated $17K sold.

Gladstone Institutional Advisory first reported a position in ZOM in Q2 2021 and held it in 3 quarters. The position peaked at $44K in Q2 2021. 110 funds tracked by Wall St. Rank hold ZOM as of Q1 2022.

  • Gladstone Institutional Advisory reported no remaining Zomedica Corp. position as of Q1 2022 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 55,058 Zomedica Corp. shares in Q1 2022, an estimated $17K.
  • Gladstone Institutional Advisory first reported a position in Zomedica Corp. in Q2 2021 and held it in 3 quarters.
  • Gladstone Institutional Advisory's Zomedica Corp. position peaked at $44K in Q2 2021.
  • 110 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2022.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2022, filed 4 May 2022.